The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
An orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Afatinib irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonyms:||dual tyrosine kinase inhibitor BIBW 2992 |
EGFR/HER2 tyrosine kinase inhibitor BIBW 2992
|Abbreviation:||EGFR/HER2 TKI BIBW 2992|
|Code name:||BIBW 2992|